肝素涂层插管生物相容性评价

doi:10.3969/j.issn.0258-8021.2023.01.014

摘要
图/表
参考文献
相关文章 (10)

全文: PDF (1041 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要对肝素涂层插管和未涂层插管设计了抗凝血、血栓形成观察以及溶血、细胞毒性、炎性和免疫反应等多种试验,从多角度综合对肝素涂层插管材料进行生物相容性评价。通过活化部分凝血活酶时间(APTT)、凝血酶原时间(PT)、纤维蛋白原降解产物(FIB)、凝血酶时间(TT)、血小板活化因子、纤维蛋白吸附等试验,测定样品的体外抗凝血性,然后通过半体内血栓形成试验,模拟插管在动物体内的使用环境和过程,观察样品引起血栓形成的状况。同时,通过溶血试验和细胞毒性试验以及炎症反应、补体激活、免疫球蛋白等检测,进一步对样品进行血液相容性评价。结果显示,肝素涂层实验组APTT和TT得到有效延长,而其他体外抗凝指标未见显著变化;在动物半体内模型试验和检测中,肝素涂层实验组6 h血栓形成的各项指标均低于未涂层对照组,表明肝素涂层通过抑制内源性凝血途径达到了预期的抗凝效果;而溶血率、细胞毒性、炎症反应、补体激活、免疫球蛋白等方面的试验结果与未涂层对照组无差异,表明肝素涂层对材料的血液相容性无不良影响。结果表明,肝素涂层显著提高了动静脉插管的体内外抗凝血性,具有良好的生物相容性,可提高临床应用的安全性。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	王玉苗
	周建业
	王爱莉
	刘碧璇

关键词 ：肝素涂层, 生物相容性, 体外评价, 半体内评价

Key words： heparin coating biocompatibility ex vivo evaluation in vitro evaluation

收稿日期: 2022-08-05

PACS:

R318

通讯作者: ^* E-mail: zhoujy@263.net

引用本文:

王玉苗, 周建业, 王爱莉, 刘碧璇. 肝素涂层插管生物相容性评价[J]. 中国生物医学工程学报, 2023, 42(1): 124-128.
Wang Yumiao, Zhou Jianye, Wang Aili, Liu Bixuan. Biocompatibility Evaluation of Heparinized Coated Cannulae. Chinese Journal of Biomedical Engineering, 2023, 42(1): 124-128.

链接本文:

http://cjbme.csbme.org/CN/10.3969/j.issn.0258-8021.2023.01.014 或 http://cjbme.csbme.org/CN/Y2023/V42/I1/124

[1] Yang F, Hou D, Wang J, et al. Vascular complications in adult postcardiotomy cardiogenic shock patients receiving venoarte rial extracorporeal membrane oxygenation[J]. Ann Intensive Care, 2018,8(1):72-80.
[2] Mwipatayi BP, Daneshmand A, Bangash HK, et al. Delayed iliacus com partment syndrome following femoral artery puncture: case report and literature review[J]. J Surg Case Rep, 2016 (6):102-105.
[3] Gott VL, Whiffen JD, Dutten RC. Heparin bonding colloidal graphite surfaces [J]. Science 1963, 142:1297-1298.
[4] 高文卿,李彤,于美丽. 生物医学材料肝素涂层技术的应用及进展[J].中国组织工程研究,2012,16(29):5445-5449.
[5] 杨剑,易定华,刘金成,等. 肝素涂层体外循环管道的制备及生物学性能评价[J].中国生物医学工程学报,2004,23:169-174.
[6] Tayama E, Hayashida N, Akasu K, et al..Biocompatibility of heparin-coated extracorporeal bypass circuits: new heparin bonded bioline system[J]. Artif Organs, 2000, 24:618-623.
[7] GB/T 16886.4-2017,医疗器械生物学评价,第4部分:与血液相互作用试验选择[S].北京:中国标准出版社,2017.
[8] GB/T 16175-2008,医用有机硅材料生物学评价实验方法[S].北京:中国标准出版社,2008.
[9] GB/T 16886.5-2017,医疗器械生物学评价,第5部分:体外细胞毒性实验[S].北京:中国标准出版社,2017.
[10] Prieto JM, Recio MC, Giner RM, et al. Influence of traditional Chinese anti-inflammatory medicinal plants on leukocyte and platelet functions [J]. J Pharm Pharmacol, 2003,55:1275-1282.
[11] Kuchinka J, Willems C, Telyshev DV, et al. Control of blood coagulation by hemocompatible material surfaces-a review [J]. Bioengineering (Basel), 2021,8(12):215-241.
[12] Velnar T, Bunc G, Klobucar R, et al. Biomaterials and host versus graft response: a short review [J]. Bosn J Basic Med Sci, 2016,16(2):82-90.
[13] Gremmel T, Ay C, Riedl J, et al. Platelet-specific markers are associated with monocyte-platelet aggregate for mation and thrombin generation potential in advanced atherosclerosis[J]. Thromb Haemost, 2015, 115 (3) :615-662.
[14] Ekdahl KN, Hong J, Hamad OA, et al. Evaluation of the blood compatibility of materials, cells, and tissues: basic concepts, test models, and practical guidelines [J]. Adv Exp Med Biol, 2013,735:257-270.
[15] Onishi A, St Ange K, Dordick JS, et al. Heparin and anticoagulation. Front Biosci (Landmark Ed), 2016,21(7):1372-1392.
[16] Lindholm L, Westerberg M, Bengtsson A, et al.A closed perfusion system with heparin coating and centrifugal pump improves cardiopulmonary bypass biocompatibility in elderly patients [J]. Ann Thorac Surg, 2004,78:2131-2138.